U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846905) titled 'Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.' on Feb. 20.
Brief Summary: Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific antibodies. These antibodies stimulate the immune system to attack tumour cells. The treatment involves an escalating dose of three subcutaneous injections every 2 to 4 days for a total of about 10 days, followed by a weekly treatment phase.
The University Hospital of Toulouse was the first centre in France to of...